Evolution of Systemic Treatment Uptake and Survival in Advanced Non-Small Cell Lung Cancer

Background: Non-small cell lung cancer (NSCLC) commonly presents at advanced stage. We previously reported systemic treatment uptake in stage IV NSCLC climbing from 55% (2009–2012) to 62% (2015–2017). Since then, first-line immunotherapy and 2nd/3rd generation tyrosine kinase inhibitors (TKIs) have...

Descripción completa

Detalles Bibliográficos
Autores principales: Stock-Martineau, Sophie, Laurie, Katie, McKinnon, Mathieu, Zhang, Tinghua, Wheatley-Price, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816185/
https://www.ncbi.nlm.nih.gov/pubmed/33704175
http://dx.doi.org/10.3390/curroncol28010008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816185/
https://www.ncbi.nlm.nih.gov/pubmed/33704175
http://dx.doi.org/10.3390/curroncol28010008

Ejemplares similares